We also show that MX2 mediates IFN inhibitory effects in melanoma, sensitizes melanoma cells to MAPK pathway targeted therapy, and regulates XAF1 that has prognostic impact in melanoma patients. The gene discussed is IFNA1; the disease is melanoma.